A rapid homogeneous immunoassay to quantify gemcitabine in plasma for therapeutic drug monitoring (TDM)

BACKGROUND: Gemcitabine (2′,2′-difluoro-2′-deoxycytidine) is a nucleoside analog used as a single agent and in combination regimens for the treatment of a variety of solid tumors. Several studies have shown a relationship between gemcitabine peak plasma concentration (C(max)) and hematological toxic...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Drug Monit
Egile Nagusiak: Kozo, Daniel, Ross, Matt W., Jarrah, Justin, Barrett, Michael, Harney, Rebecca L., Courtney, Jodi B., Baburina, Irina, Holleran, Julianne L., Beumer, Jan H., Peters, Godefridus J., Honeywell, Richard J., Salamone, Salvatore J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5460533/
https://ncbi.nlm.nih.gov/pubmed/28490046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FTD.0000000000000402
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak